Clark Eliana 4
4 · Intellia Therapeutics, Inc. · Filed Jan 6, 2025
Insider Transaction Report
Form 4
Clark Eliana
EVP, Chief Technical Officer
Transactions
- Sale
Common Stock
2025-01-02$12.03/sh−556$6,689→ 71,470 total - Sale
Common Stock
2025-01-03$12.18/sh−7,422$90,400→ 64,048 total
Footnotes (2)
- [F1]Sale of 556 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2024.
- [F2]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person.